Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating, or less than 6 weeks post-partum~* current symptomatic heart failure (NYHA Class II-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metformin + glimepiride + pioglitazone + albiglutide placebo (Type: ACTIVE_COMPARATOR): Metformin + glimepiride + pioglitazone + matching albiglutide placebo
- metformin + glimepiride + pioglitazone placebo + albiglutide (Type: EXPERIMENTAL): Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
- met + glimepiride + pioglitazone placebo + albiglutide placebo (Type: ACTIVE_COMPARATOR): metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).